Table 1. Meta-analyses of secondary outcomes.
| Secondary outcomes | Number of included studies | Meta-analyses | Quality of evidence | |
|---|---|---|---|---|
| ES (95% CI) | I2 (%) | |||
| Number of lobes affected | ||||
| 1 | 31 | 0.13 (0.09–0.18) | 84.23 | Low |
| 2 | 16 | 0.14 (0.09–0.19) | 82.10 | Low |
| 3 | 17 | 0.11 (0.09–0.14) | 59.42 | Low |
| 4 | 14 | 0.15 (0.09–0.21) | 87.71 | Low |
| 5 | 18 | 0.42 (0.29–0.56) | 96.22 | Low |
| Location of lobe involvement | ||||
| Right upper lobe | 21 | 0.62 (0.56–0.69) | 64.55 | Low |
| Right middle lobe | 21 | 0.51 (0.43–0.59) | 78.15 | Low |
| Right lower lobe | 28 | 0.84 (0.78–0.90) | 70.66 | Low |
| Left upper lobe | 23 | 0.69 (0.61–0.76) | 75.81 | Low |
| Left lower lobe | 26 | 0.81 (0.74–0.87) | 72.75 | Low |
| Distribution of lesion | ||||
| Peripheral | 36 | 0.65 (0.55–0.74)) | 94.02 | Low |
| Central | 13 | 0.03 (0.02–0.05) | 52.09 | Low |
| Mixed | 22 | 0.45 (0.37–0.53) | 87.06 | Low |
| Others | ||||
| Rounded morphology | 7 | 0.42 (0.27–0.58) | 76.26 | Low |
| Linear opacities | 18 | 0.27 (0.16–0.38) | 90.01 | Low |
| Crazy-paving pattern | 27 | 0.29 (0.21–0.39) | 90.57 | Low |
| Air bronchogram | 40 | 0.42 (0.33–0.50) | 93.78 | Low |
| Interlobular septum thickening | 22 | 0.44 (0.33–0.57) | 91.19 | Low |
| Pleural thickening | 16 | 0.30 (0.12–0.51) | 95.88 | Low |
| Halo sign | 12 | 0.22 (0.09–0.39) | 90.80 | Low |
| Reverse halo sign | 8 | 0.02 (0.01–0.04) | 0.00 | Moderate |
| Pleural effusion | 67 | 0.01 (0.00–0.02) | 56.97 | Low |
| Lymphadenopathy | 49 | 0.00 (0.00–0.01) | 68.31 | Low |
ES, estimated size; CI, confidence interval.